German Boehringer Ingelheim has changed the focus of clinical studies in a million-dollar collaboration with Zealand Pharma. It delays the project and the potential milestone payments for the Danish biotech company. At the same time, Zealand postpones one of its own phase III programs.
Marcus Desimoni, CFO in GN Group and interim CEO in GN Hearing, declines to reveal whether he is a candidate for permanently taking over the top position in the hearing device unit.
Brussels-based biotech company Camel-IDS has raised EUR 37 million (USD 41.83 million) to continue the development of the phase I candidate against an especially aggressive form of breast cancer. Danish Novo Seeds is among the lead investors.
A new international research center focusing on antimicrobial resistance will be placed in Denmark. The center will employ between 400 and 500 people.
Stephan Thorgrimsen and Sune Justesen from the Danish biotech company Immunitrack have managed a sevenfold increase in profit that, for the first time, exceeds DKK 1 million. Moreover, the duo expects to triple the annual sales in future.
Together with Eli Lilly, US-based Sigilon is developing a diabetes cell therapy that is to function as an insulin-producing artificial pancreas. Sigilon's co-founder, Robert Langer, hopes the therapy can replace insulin and even cure type 1 diabetes.
After just few months on the market, Danish hearing aid group William Demant no longer offers one of the company's in-ear devices. Technical problems are the reason behind the recall that, after all, only have marginal impact on the company's finances.
Representatives from the US army recently visited Copenhagen to search for overlooked medical research in war-related disorders. The military offers to finance relevant projects all the way through the clinical phases.
Researchers from University of Copenhagen have discovered exactly how inflammation hinders insulin production in patients with type 2 diabetes. According to one of the professors, the discovery could bring about a whole new class of diabetes drugs based on one of the most promising fields of biotechnology: RNA.
Danish researcher Philip Just Larsen has conducted diabetes research for companies like Novo Nordisk, Sanofi and Eli Lilly. Now, he is CSO in German Grünenthal and aims to develop the future's pain killers and maybe even find a solution to the deadly opioid addiction.
Timm Jessen co-founded 2curex in 2006 and is now CEO of Topas, a German biotech company using nanotechnology for developing drugs against autoimmune diseases. The company aims to take a candidate against a rare skin disorder to the clinic in 2019 and follow up with a diabetes therapy in 2020.
Roche is the second best mid-sized workplace in Denmark 2018. This is according to an analysis from the consultancy firm Great Place to Work. And for the twelfth year in a row, the Danish unit of the drug group takes a place in top 5.
A comment on an investor conference cost Danish biotech company Rhovac more than DKK 100 million of its stock market value.
Ferring's newly appointed president of the executive committee, Per Falk, will push the company towards the lead position in innovation that Ferring, in his opinion, lost at the turn of the millennium. And the Danish research department plays a pivotal role in his plan.
Last week, CEO in GN Hearing, Anders Hedegaard, announced his resignation. The search for a new top manager for the Danish hearing aid group has begun, and Hedegaard's successor might very well come from one of the company's closest competitors. Headhunters especially point towards one candidate.
The hearing aid group Widex has retracted its application to the European Commission for merging with EQT-owned Sivantos. The company does not give any reasons but maintains its plans about merging.
Less than a year after Embark Biotech was spun out from University of Copenhagen, the new Danish biotech company has entered a comprehensive collaboration with Novo Nordisk to develop a brand new class of obesity drugs.
Danish Reapplix is looking for funding for the further development of the company's biological patch to heal diabetic foot ulcers. However, the CEO will neither confirm nor deny an eventual upcoming IPO.
This week, the National Hospital of Denmark relieved professor Peter Gøtzsche of his duties. The current deputy director of Nordic Cochrane Center will take over Gøtzsche's position.
Award-winning researcher Robert Langer has founded 40 companies, holds more than 1300 patents and is in charge of 60 researchers in his own laboratory on MIT. But the road to success was paved with refusals, criticism and depression.
The candidate Lu AF35700's failure against treatment-resistant schizophrenia disappoints Lundbeck as well as its shareholders, and the company's CFO gives up the candidate in this indication.
More than half of the drugs, that were recently impounded on their way to Denmark, were non-approved impotence treatments. The Viagra manufacturer Pfizer collaborates with 151 countries to stop the sales of illegal copies and falsifications.
With the announcement of new products and partnerships, Novo Nordisk reveals bits of the plans for the its entry into the digital health market.
Hans Schambye, CEO in Danish Galecto Biotech, is very content with last week's million-dollar investment in his company from new as well as current investors.
Novo Seeds invests DKK 100 million more in Danish biotech company Galecto and becomes the principal shareholder - in every way a significant investment and according to Senior Partner, Stephan Christgau, the biggest so far in the venture fund's history.
